Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

This study has been completed.
Information provided by (Responsible Party):
Omicron Pharmaceuticals Identifier:
First received: January 29, 2011
Last updated: May 18, 2013
Last verified: May 2013

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Condition Intervention Phase
Drug: Ateronon
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Resource links provided by NLM:

Further study details as provided by Omicron Pharmaceuticals:

Primary Outcome Measures:
  • to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • to evaluate the potential effectiveness of Ateronon in lowering pulse rate as well systolic and diastolic blood pressure in patients with demonstrated coronary disease [ Time Frame: Baseline and 3 months ] [ Designated as safety issue: Yes ]

Enrollment: 100
Study Start Date: May 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Active Comparator: Ateronon Drug: Ateronon
Ateronon daily for 3 months


Ages Eligible for Study:   35 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and Women with demonstrated Coronary Disease
  • AtheroAbzyme positive during screening process
  • Elevated Total Cholesterol
  • Willingness to take study nutritional supplement once a day for 3 months

Exclusion Criteria:

  • Women who are pregnant, nursing or intend pregnancy during the period of treatment
  • Known milk, soy or whey allergy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01287182

Rafic Hariri University Hospital
Beirut, Bir Hasan, Lebanon
Sponsors and Collaborators
Omicron Pharmaceuticals
  More Information

No publications provided

Responsible Party: Omicron Pharmaceuticals Identifier: NCT01287182     History of Changes
Other Study ID Numbers: OP2912011
Study First Received: January 29, 2011
Last Updated: May 18, 2013
Health Authority: United States: Food and Drug Administration
Lebanon: Institutional Review Board

Keywords provided by Omicron Pharmaceuticals:
Asymptomatic Myocardial Ischemic patients

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Vascular Diseases processed this record on November 23, 2014